CAR-T疗法在淋巴瘤领域的探索之旅
综述总结抗CD19 CAR-T治疗复发难治性大B细胞淋巴瘤的临床结局:约三分之一患者获持久完全缓解并可能治愈,多数无效或复发;文章梳理耐药机制并讨论克服耐药的策略。
要点
- 抗CD19 CAR-T已改变复发难治大B细胞淋巴瘤治疗格局。
- 长期随访约三分之一患者获持久完全缓解,可能治愈。
- 多数患者原发耐药或复发,耐药机制与克服策略是重点。
核心结论
- 抗CD19 CAR-T可使部分复发难治大B细胞淋巴瘤患者获持久完全缓解,但多数患者无效或复发。
研究设计与样本
- 综述,总结CART免疫治疗在B细胞非霍奇金淋巴瘤的当前临床结局、复发机制与耐药策略。
主要发现
- 长期随访数据显示约三分之一患者获 prolonged complete remission 并可能治愈。
- 多数患者对CD19 CAR-T无应答或在治疗后最终复发。
关键数值与推荐
- 约三分之一患者获持久完全缓解(prolonged complete remission),其余多数无效或复发。
临床怎么用
- 抗CD19 CAR-T广泛用于复发难治侵袭性大B细胞淋巴瘤。
- 需识别耐药机制并探索克服耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells (CART) therapies have changed and continue to change the treatment paradigms for B-cell malignancies because they can achieve durable complete remission in patients in whom multiple lines of treatment have failed. These unprecedented results have led to the widespread use of anti-CD19 CART therapy for patients with relapsed and refractory aggressive large B-cell lymphomas. While long-term follow-up data show that about one-third of patients achieve prolonged complete remission and are potentially cured, the majority of patients either do not respond to CD19 CART therapy or eventually relapse after CD19 CART therapy. These results are, on the one hand, driving intense research into identifying mechanisms of relapse and, on the other hand, inspiring the development of novel strategies to overcome resistance. This review summarizes current clinical outcomes of CART immunotherapy in B-cell non-Hodgkin lymphomas, describes the most up-to-date understanding of mechanisms of relapse and discusses novel strategies to address resistance to CART therapy. We are indeed at the beginning of a scientific trek to explore the mechanisms of resistance, seek out new, more effective treatment approaches based on these discoveries and to boldly go where no other therapy has gone before!
引用
- Ghilardi G, Braendstrup P, Chong EA, et al. CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. Br J Haematol. 2020. PMID: 33222167. doi:10.1111/bjh.17191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。